Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Oral FGFR1-3 Inhibitor Boosted Height Velocity in Common Genetic Growth Disorder

The trial showed the largest mean height gain reported in a Phase 3 achondroplasia study, and no drug-related serious adverse events were seen.

Summary by MedPage Today
(MedPage Today) -- Treatment with a once-daily FGFR1-3 tyrosine kinase inhibitor led to significant increases in growth among children with achondroplasia, the phase III PROPEL 3 study showed. The least-squares mean change from baseline in the...

5 Articles

WBOC 16WBOC 16
+3 Reposted by 3 other sources
Center

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral

Read Full Article
MedPage TodayMedPage Today
Center

Oral FGFR1-3 Inhibitor Boosted Height Velocity in Common Genetic Growth Disorder

(MedPage Today) -- Treatment with a once-daily FGFR1-3 tyrosine kinase inhibitor led to significant increases in growth among children with achondroplasia, the phase III PROPEL 3 study showed. The least-squares mean change from baseline in the...

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MedPage Today broke the news in New York, United States on Sunday, June 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Carroll County, Maryland icon

Carroll County, Maryland

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal